CD274 and hepatocellular carcinoma: In recent years, significant advances have been made in the diagnosis, treatment, and prognosis of HCC, such as the PD-L1 inhibitor atezolizumab, combined with the anti-angiogenic agent bevacizumab, which has achieved success in the first-line treatment of advanced HCC, however, treatment outcomes for HCC patients remain unsatisfactory (6).